X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (96435) 96435
Publication (11671) 11671
Newsletter (1716) 1716
Book Review (857) 857
Book Chapter (414) 414
Conference Proceeding (125) 125
Newspaper Article (63) 63
Dissertation (54) 54
Magazine Article (27) 27
Book / eBook (24) 24
Transcript (14) 14
Reference (13) 13
Government Document (8) 8
Data Set (7) 7
Web Resource (7) 7
Trade Publication Article (5) 5
Streaming Video (3) 3
Paper (2) 2
Presentation (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (50434) 50434
animals (50420) 50420
index medicus (39811) 39811
male (23904) 23904
mice (19873) 19873
tyrosine (19612) 19612
rats (18848) 18848
female (17603) 17603
oncology (17278) 17278
biochemistry & molecular biology (16237) 16237
phosphorylation (15638) 15638
cancer (12213) 12213
cell biology (12168) 12168
signal transduction (11166) 11166
neurosciences (10985) 10985
cells, cultured (9734) 9734
pharmacology & pharmacy (9464) 9464
expression (9411) 9411
tyrosine kinase (9249) 9249
research (8688) 8688
activation (8471) 8471
signal transduction - drug effects (8378) 8378
cell line, tumor (8258) 8258
analysis (8040) 8040
tyrosine - metabolism (7846) 7846
proteins (7658) 7658
protein-tyrosine kinases - metabolism (7518) 7518
apoptosis (7286) 7286
tyrosine phosphorylation (7274) 7274
enzyme inhibitors - pharmacology (7068) 7068
protein-tyrosine kinases - antagonists & inhibitors (7043) 7043
kinases (6883) 6883
dose-response relationship, drug (6878) 6878
article (6866) 6866
mutation (6667) 6667
tyrosine kinase inhibitor (6645) 6645
cell line (6636) 6636
middle aged (6602) 6602
hematology (6132) 6132
adult (6021) 6021
tyrosine 3-monooxygenase - metabolism (5779) 5779
rats, sprague-dawley (5677) 5677
antineoplastic agents - pharmacology (5557) 5557
antineoplastic agents - therapeutic use (5450) 5450
care and treatment (5427) 5427
cells (5386) 5386
aged (5296) 5296
time factors (5224) 5224
phosphorylation - drug effects (5171) 5171
physiological aspects (4950) 4950
protein kinase inhibitors - pharmacology (4915) 4915
gene expression (4742) 4742
apoptosis - drug effects (4680) 4680
phenols (4591) 4591
health aspects (4495) 4495
immunology (4487) 4487
in-vitro (4413) 4413
research article (4380) 4380
tyrosine kinase inhibitors (4365) 4365
tyrosine - analogs & derivatives (4297) 4297
immunohistochemistry (4293) 4293
protein-tyrosine kinase (4289) 4289
in-vivo (4256) 4256
chemotherapy (4228) 4228
tumors (4167) 4167
receptor (4152) 4152
cell proliferation - drug effects (4137) 4137
genetic aspects (4133) 4133
tumor cells, cultured (4048) 4048
kinetics (4010) 4010
multidisciplinary sciences (3993) 3993
protein kinase inhibitors - therapeutic use (3977) 3977
disease models, animal (3963) 3963
mice, inbred c57bl (3938) 3938
blotting, western (3876) 3876
inhibition (3837) 3837
oxidative stress (3796) 3796
growth-factor receptor (3793) 3793
signal transduction - physiology (3693) 3693
epidermal growth factor (3630) 3630
signal-transduction (3614) 3614
neurons (3609) 3609
dopamine (3604) 3604
endocrinology & metabolism (3569) 3569
molecular sequence data (3563) 3563
imatinib mesylate (3503) 3503
protein (3488) 3488
medicine (3484) 3484
gene-expression (3468) 3468
metastasis (3457) 3457
angiogenesis (3455) 3455
dopamine - metabolism (3422) 3422
cell division - drug effects (3363) 3363
brain (3338) 3338
growth (3274) 3274
enzyme activation - drug effects (3259) 3259
transfection (3220) 3220
treatment outcome (3219) 3219
rats, wistar (3180) 3180
physiology (3178) 3178
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (97220) 97220
Chinese (262) 262
German (261) 261
Russian (242) 242
French (235) 235
Japanese (160) 160
Spanish (32) 32
Hungarian (29) 29
Polish (29) 29
Italian (27) 27
Korean (14) 14
Portuguese (7) 7
Czech (6) 6
Dutch (6) 6
Ukrainian (6) 6
Danish (4) 4
Norwegian (4) 4
Swedish (4) 4
Bulgarian (3) 3
Croatian (2) 2
Turkish (2) 2
Arabic (1) 1
Finnish (1) 1
Serbian (1) 1
Slovenian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cell Reports, ISSN 2211-1247, 09/2016, Volume 16, Issue 10, pp. 2576 - 2592
The mechanisms underlying Zika virus (ZIKV)-related microcephaly and other neurodevelopment defects remain poorly understood. Here, we describe the derivation... 
NEURAL PROGENITORS | LONG-TERM | HUMAN BRAIN | ADAPTER | CENTRAL-NERVOUS-SYSTEM | INFECTION | MICE | BINDING KINASE 1 | ORGANOIDS | INNATE IMMUNITY | CELL BIOLOGY | Neocortex - pathology | Neurons - pathology | Transcription, Genetic - drug effects | Brain - embryology | Neuroglia - ultrastructure | Neuroglia - pathology | Humans | Brain - virology | Centrosome - drug effects | Gene Expression Profiling | Microcephaly - virology | Neural Stem Cells - ultrastructure | Zika Virus Infection - virology | Neural Stem Cells - immunology | Neuroepithelial Cells - immunology | Neuroprotective Agents - pharmacology | Spinal Cord - pathology | Microcephaly - pathology | Neuroepithelial Cells - virology | Nucleosides - pharmacology | Fetus - virology | Cell Death - drug effects | Phosphorylation - drug effects | Neurons - drug effects | Protein-Serine-Threonine Kinases - metabolism | Zika Virus - pathogenicity | Proto-Oncogene Proteins - metabolism | Zika Virus - ultrastructure | Neurons - virology | Virus Replication - drug effects | Neuroepithelial Cells - ultrastructure | Immunity, Innate - drug effects | Zika Virus Infection - pathology | Neural Stem Cells - virology | Zika Virus - physiology | Zika Virus - drug effects | Mitochondria - metabolism | Mitochondria - drug effects | Receptor Protein-Tyrosine Kinases - metabolism | Neural Stem Cells - enzymology | Centrosome - metabolism | Mitosis - drug effects | Brain - pathology | Protein Kinase Inhibitors - pharmacology | Neuroglia - virology | Neuroepithelial Cells - drug effects | Neurons/pathology | Zika Virus/pathogenicity | Mitochondria/metabolism | Virus Replication/drug effects | Microcephaly/pathology | Neurons/drug effects | Protein-Serine-Threonine Kinases/metabolism | Neural Stem Cells/immunology | Neuroglia/ultrastructure | Neuroepithelial Cells/drug effects | Neuroepithelial Cells/virology | Life Sciences | Brain/pathology | Zika Virus/drug effects | Brain/embryology | Mitochondria/drug effects | Fetus/virology | Neocortex/pathology | Neuroglia/pathology | Cell Death/drug effects | Mitosis/drug effects | Transcription, Genetic/drug effects | Nucleosides/pharmacology | Neural Stem Cells/enzymology | Neural Stem Cells/ultrastructure | Neuroepithelial Cells/ultrastructure | Receptor Protein-Tyrosine Kinases/metabolism | Microcephaly/virology | Proto-Oncogene Proteins/metabolism | Neuroprotective Agents/pharmacology | Zika Virus/ultrastructure | Neuroepithelial Cells/immunology | Brain/virology | Immunity, Innate/drug effects | Spinal Cord/pathology | Zika Virus/physiology | Neuroglia/virology | Microbiology and Parasitology | Zika Virus Infection/pathology | Neurons/virology | Zika Virus Infection/virology | Neural Stem Cells/virology | Centrosome/drug effects | Protein Kinase Inhibitors/pharmacology | Centrosome/metabolism | Phosphorylation/drug effects
Journal Article
Nature, ISSN 0028-0836, 04/2015, Volume 520, Issue 7547, pp. 368 - 372
Drug resistance invariably limits the clinical efficacy of targeted therapy with kinase inhibitors against cancer(1,2). Here we show that targeted therapy with... 
CNS CELL-TYPES | MELANOMA | METASTASIS | MICROENVIRONMENT | TRANSLATIONAL PROFILING APPROACH | MULTIDISCIPLINARY SCIENCES | RAF INHIBITOR RESISTANCE | ACQUIRED-RESISTANCE | KINASE INHIBITORS | DRUG-RESISTANCE | CANCER CHEMORESISTANCE | Lung Neoplasms - drug therapy | Adenocarcinoma - pathology | Clone Cells - drug effects | Humans | Lung Neoplasms - metabolism | Lung Neoplasms - pathology | Proto-Oncogene Proteins c-fos - deficiency | Adenocarcinoma - metabolism | Neoplasm Metastasis - drug therapy | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Female | Proto-Oncogene Proteins c-akt - metabolism | Melanoma - metabolism | Tumor Microenvironment - drug effects | Cell Survival - drug effects | Melanoma - pathology | Down-Regulation - drug effects | Enzyme Activation - drug effects | Adenocarcinoma - drug therapy | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Cell Movement - drug effects | Lung Neoplasms - secretion | Melanoma - secretion | Animals | Clone Cells - pathology | Metabolome - drug effects | Signal Transduction - drug effects | Neoplasm Metastasis - pathology | Protein Kinase Inhibitors - therapeutic use | Melanoma - drug therapy | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Adenocarcinoma - secretion | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Drug Resistance, Neoplasm - drug effects | Antimitotic agents | Pharmaceutical research | Care and treatment | Oncology, Experimental | Dosage and administration | Research | Drug therapy | Drug resistance | Antineoplastic agents | Tumors | Cancer | Melanoma | Mutation | Metastasis | Kinases | Cancer therapies
Journal Article
Nature Communications, ISSN 2041-1723, 2012, Volume 3, Issue 1, p. 1208
Journal Article
Journal of the National Cancer Institute, ISSN 0027-8874, 2012, Volume 104, Issue 2, pp. 93 - 113
With the advent of targeted agents for the treatment of renal cell carcinoma (RCC), overall survival has improved, and patients are being treated continuously... 
TYROSINE KINASE INHIBITORS | CONTROLLED-TRIAL | INTERFERON-ALPHA | SUNITINIB TREATMENT | CANCER-PATIENTS | VENOUS THROMBOEMBOLISM | ONCOLOGY | HEART-FAILURE | DOUBLE-BLIND | EXPANDED ACCESS PROGRAM | ENDOTHELIAL GROWTH-FACTOR | Niacinamide - analogs & derivatives | Hypothyroidism - chemically induced | Pneumonia - therapy | Anorexia - therapy | Humans | Drug Eruptions - therapy | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Kidney Neoplasms - metabolism | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | Vascular Endothelial Growth Factor A - antagonists & inhibitors | Weight Loss - drug effects | Benzenesulfonates - adverse effects | Bevacizumab | TOR Serine-Threonine Kinases - antagonists & inhibitors | Pyridines - adverse effects | Antineoplastic Agents - adverse effects | Pneumonia - chemically induced | Pyrroles - adverse effects | Antineoplastic Agents - pharmacology | Carcinoma, Renal Cell - drug therapy | Everolimus | Hypothyroidism - therapy | Wound Healing - drug effects | Molecular Targeted Therapy - methods | Sirolimus - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Sirolimus - analogs & derivatives | Europe | Gastrointestinal Tract - drug effects | Cardiovascular System - drug effects | Evidence-Based Medicine | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Anorexia - chemically induced | Kidney Neoplasms - drug therapy | Protein-Tyrosine Kinases - antagonists & inhibitors | Antimitotic agents | Drugs | Complications and side effects | Care and treatment | Adverse and side effects | Carcinoma, Renal cell | Research | Drug therapy | Antineoplastic agents
Journal Article
Nature Reviews Clinical Oncology, ISSN 1759-4774, 07/2016, Volume 13, Issue 7, pp. 431 - 446
Around 15 years ago, imatinib mesylate (Gleevec (R) or Glivec (R), Novartis, Switzerland) became the very first 'targeted' anticancer drug to be clinically... 
CHRONIC MYELOGENOUS LEUKEMIA | CYTOTOXIC T-CELLS | KILLER DENDRITIC CELLS | ONCOLOGY | MINOR HISTOCOMPATIBILITY ANTIGENS | HEMATOPOIETIC STEM-CELLS | ACUTE LYMPHOBLASTIC-LEUKEMIA | TYROSINE KINASE INHIBITOR | GASTROINTESTINAL STROMAL TUMORS | COMPLETE MOLECULAR RESPONSE | CHRONIC MYELOID-LEUKEMIA | Tumor Escape - drug effects | Humans | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy | Antineoplastic Agents - therapeutic use | B7 Antigens - immunology | Drug Approval | Protein-Tyrosine Kinases - immunology | Hematopoiesis - drug effects | Natural Cytotoxicity Triggering Receptor 3 - drug effects | Imatinib Mesylate - therapeutic use | Immunity, Cellular - drug effects | Immune Tolerance - immunology | T-Lymphocytes - drug effects | Protein-Tyrosine Kinases - drug effects | Killer Cells, Natural - immunology | Molecular Chaperones - drug effects | Natural Cytotoxicity Triggering Receptor 3 - immunology | Vascular Endothelial Growth Factor A - drug effects | Leukemia, Myelogenous, Chronic, BCR-ABL Positive - immunology | Molecular Chaperones - immunology | Molecular Targeted Therapy - methods | Gastrointestinal Stromal Tumors - immunology | Immune Tolerance - drug effects | Tumor Escape - immunology | Antigens, Neoplasm - immunology | Antineoplastic Agents - immunology | B7 Antigens - drug effects | Vascular Endothelial Growth Factor A - immunology | Immunologic Surveillance - drug effects | Forecasting | Immunologic Surveillance - immunology | Hematopoiesis - immunology | Imatinib Mesylate - immunology | Gastrointestinal Stromal Tumors - drug therapy | T-Lymphocytes - immunology | Killer Cells, Natural - drug effects | Antigens, Neoplasm - drug effects | Tyrosine | Care and treatment | Analysis | Immunotherapy | B cells | Drug approval | Cancer
Journal Article
Nature, ISSN 0028-0836, 2014, Volume 514, Issue 7520, pp. 112 - 116
Chemoresistance is a serious limitation of cancer treatment(1). Until recently, almost all the work done to study this limitation has been restricted to tumour... 
CANCER-CELLS | ACTIVATION | METASTASIS | MICROENVIRONMENT | ANGIOGENESIS | INFLAMMATION | MULTIDISCIPLINARY SCIENCES | RESISTANCE | FOCAL ADHESION KINASE | NF-KAPPA-B | EXPRESSION | Doxorubicin - therapeutic use | Apoptosis - drug effects | Apoptosis - radiation effects | Humans | NF-kappa B - metabolism | Cell Nucleus - metabolism | Neoplasms - genetics | DNA Damage - genetics | Neoplasms - radiotherapy | Phosphorylation - drug effects | DNA Damage - drug effects | Endothelial Cells - metabolism | Focal Adhesion Protein-Tyrosine Kinases - metabolism | Focal Adhesion Protein-Tyrosine Kinases - deficiency | Neoplasms - drug therapy | Focal Adhesion Protein-Tyrosine Kinases - genetics | Drug Resistance, Neoplasm - genetics | Animals | Active Transport, Cell Nucleus - drug effects | Cell Proliferation - drug effects | Mice | Cell Nucleus - drug effects | Neoplasms - pathology | Endothelial Cells - enzymology | Cytokines - biosynthesis | Doxorubicin - pharmacology | Cell Proliferation - radiation effects | Drug Resistance, Neoplasm - drug effects | Endothelial Cells - drug effects | Tyrosine | Complications and side effects | Care and treatment | DNA damage | Oncology, Experimental | Genetic research | Genetic aspects | Research | Drug resistance | Phosphotransferases | Health aspects | Cancer | Cell growth | Chemotherapy | Cytokines | Melanoma | Lymphomas | Radiation therapy | Kinases | Cancer therapies | Deoxyribonucleic acid--DNA | Cell adhesion & migration | Tumors
Journal Article
Journal of Clinical Investigation, ISSN 0021-9738, 05/2015, Volume 125, Issue 5, pp. 1780 - 1789
Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases. Currently, more than 25 oncology drugs that target... 
MEDICINE, RESEARCH & EXPERIMENTAL | ONCOGENIC ACTIVATION | PROTEIN-KINASE | TUMOR-INFILTRATING MACROPHAGES | ADAPTIVE RESISTANCE | ACQUIRED-RESISTANCE | CLINICAL RESISTANCE | DIACYLGLYCEROL KINASES | RECEPTOR TYROSINE KINASE | IMATINIB MESYLATE | ANTITUMOR EFFICACY | Immunotherapy - methods | Apoptosis - drug effects | Humans | Substrate Specificity | Drug Resistance, Neoplasm | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Neoplasms - genetics | Protein Processing, Post-Translational - drug effects | Drug Design | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | Neoplasm Proteins - genetics | Molecular Targeted Therapy - methods | Neoplasms - enzymology | Gene Fusion | Enzyme Activation - drug effects | Neoplasms - drug therapy | Drug Synergism | Point Mutation | Gene Amplification | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Oncogene Proteins, Fusion - antagonists & inhibitors | Signal Transduction - physiology | Protein Kinase Inhibitors - pharmacology | Apoptosis - physiology | Enzyme inhibitors | Physiological aspects | Research | Drug therapy | Phosphotransferases | Health aspects | Cancer | Proteins | Phosphorylation | Gene amplification | Biology | Regulation | Genomes | Mutation | Metastasis | Kinases | Phosphatase | Tumors | Review
Journal Article
The Lancet Oncology, ISSN 1470-2045, 12/2017, Volume 18, Issue 12, pp. 1590 - 1599
Journal Article